Challenges and Solutions in Lipid-Lowering Therapy in Women: From Gaps to Practice-Changing Advances
Atherosclerotic cardiovascular disease (ASCVD) events are among the leading causes of death in women in the US and globally.
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC
  • 1.50 Participation
Cost $0.00
Escape Room Experience: Individualizing Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes
The coexistence of type 2 diabetes and chronic kidney disease significantly exacerbates cardiovascular and renal morbidity and mortality compared to either condition alone. Even with the advent of newer therapies in patients with T2D and CKD, such as sodium-glucose cotransporter-2 (SGLT-2) inhibi
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Cost $0.00
Breaking Through Inertia: How to Initiate and Maintain Insulin Therapy in Patients with Type 2 Diabetes
This interactive infographic covers a variety of topics surrounding the role of insulin therapy in type 2 diabetes (T2D) management, including practical pearls for initiation and maintenance of insulin therapy, how insulin therapy fits in with other T2D treatment options, a
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 1.50 AAFP
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Cost $0.00
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects an estimated 25-30% of people in the United States and can often progress to Metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis.
Category
  • CMHC
  • TME
Format
  • Self-study / Enduring
Credits
  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
  • 0.75 Participation
Cost $0.00
Exploring Novel Strategies for LDL-C Combination Therapy to Decrease ASCVD Risk: A Paradigm Shift
Effectively and safely lowering LDL-C is essential to prevent and reduce the risk of recurrent ASCVD events.
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC
  • 1.50 CDE
  • 1.50 Participation
Cost $0.00
According to the Patient: Alopecia Areata in Adolescence
The management of AA in adolescents presents various challenges to dermatology professionals, including identification of AA, limited effective treatment options, and high disease burden.
Category
  • LivDerm
  • TME
Format
  • Video
Credits
  • 1.00 AAPA Category I CME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Cost $0.00
Advances in Non-Steroidal Topicals: PDE-4 Inhibitors for Seborrheic Dermatitis and Beyond
Traditional treatments for seborrheic dermatitis, including oral and topical steroids, present a variety of challenges including lack of efficacy, adverse events with long-term use, limitations for adherence, and the inability to treat both hair- and non-hair-bearing areas.
Category
  • LivDerm
  • TME
Format
  • Video
Credits
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
  • 0.75 Participation
Cost $0.00
Clinical Insights into Psoriasis in Patients of Color: Bringing New Data to Light
Various gaps in the management of psoriasis in patients with SOC persist due to a lack of training for dermatology practitioners. As a result, patients with SOC are often misdiagnosed, experience more severe disease, and experience more disease burden.
Category
  • LivDerm
Format
  • Video
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Cost $0.00
Understanding the Role of Lp(a) as a CV Risk Marker to Therapeutic Target in the Prevention of ASCVD
Residual ASCVD risk may be present even after the optimization of LDL-C levels and increasing evidence has suggested that elevated Lp(a) is an emerging CVD risk factor that has been shown to be a causal CVD risk factor in epidemiological and genetic studies, as well as enha
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC
  • 1.50 CDE
  • 1.50 Participation
Cost $0.00
Ace the Case Challenge Series: Exploring Novel Strategies for LDL-C Combination Therapy to Decrease ASCVD Risk
Effectively managing high cholesterol level and safely lowering LDL-C is crucial for preventing and reducing the risk of adverse cardiovascular events. However, achieving LDL-C goals remains suboptimal, particularly in high-risk and very high-risk patients.
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
  • 0.75 Participation
Cost $0.00

Pages